Ashish Kumar Kakkar

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 15

Top Topics

Ultra High Performance Liquid Chromatography

Coronavirus Disease

Top Venues

Expert review of clinical pharmacology

Expert opinion on drug safety

Expert review of neurotherapeutics

Antibiotics (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Jeffrey Pradeep Raj, Nithya Jaideep Gogtay, Avaneesh Pandey, Ashish Kumar Kakkar, Nusrat Shafiq, Padmaja Mekala, Usharani Pingali, Arun Prasath Raju, Surulivel Rajan M, Nilima Arun Kshirsagar
Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID-19) in India. Journal of clinical pharmacology 62 (11) (2022)
Harmanjit Singh, Jatin Sharma, Pallavi Sikarwar, Ashish Kumar Kakkar
Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: current evidence and future directions. Expert review of clinical pharmacology 16 (1) (2022)
Harmanjit Singh, Jatin Sharma, Pallavi Sikarwar, Ashish Kumar Kakkar
Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: current evidence and future directions. Expert review of clinical pharmacology (2022)
Harmanjit Singh, Jatin Sharma, Pallavi Sikarwar, Ashish Kumar Kakkar
Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: current evidence and future directions. Expert review of clinical pharmacology 16 (1) (2022)
Rachna Rohilla, Ashish Kumar Kakkar, Krishna Divyashree, Ritin Mohindra, Vikas Suri
Recombinant protein subunit COVID-19 vaccine-induced Guillain-Barré Syndrome in an adolescent: A case report. British journal of clinical pharmacology (2022)
Harmanjit Singh, Jatin Sharma, Pallavi Sikarwar, Ashish Kumar Kakkar
Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer? Current evidence and future directions. Expert review of clinical pharmacology (2022)
Ashish Kumar Kakkar, Nusrat Shafiq, Neeru Sahni, Ritin Mohindra, Navjot Kaur, Nanda Gamad, Aditi Panditrao, Dimple Kondal, Samir Malhotra, Praveen Kumar M, Rachna Rohilla, Samiksha Bhattacharjee, Ankit Kumar, Ritika Kondel Bhandari, Avaneesh Kumar Pandey, Imraan Rather, Chakrant Mothsara, Cvn Harish, Devaraj Belavagi, Gopal Vishwas
Assessment of Appropriateness of Antimicrobial Therapy in Resource-Constrained Settings: Development and Piloting of a Novel Tool-AmRAT. Antibiotics (Basel, Switzerland) 10 (2) (2021)
Praveen Kumar-M, Ritin Mohindra, Ashish Bhalla, Nusrat Shafiq, Vikas Suri, Deepa Kumari, Avaneesh Kumar Pandey, Ankur Gupta, Parul Chawla Gupta, Amol N Patil, Ashish Kumar Kakkar, Samir Malhotra
System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. Expert review of anti-infective therapy 19 (10) (2021)
Harmanjit Singh, Prerna Chauhan, Jasbir Singh, null Saurabh, C S Gautam, Ashish Kumar Kakkar
Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection? Expert review of clinical pharmacology 14 (3) (2021)
Ashish Kumar Kakkar
Pharmaceutical price regulation and its impact on drug innovation: mitigating the trade-offs. Expert opinion on therapeutic patents 31 (3) (2021)
Rubina Mulchandani, Tanica Lyngdoh, Ashish Kumar Kakkar
Statin use and safety concerns: an overview of the past, present, and the future. Expert opinion on drug safety 19 (8) (2020)
Praveen Kumar-M, Rahul Mahajan, Soundappan Kathirvel, Naveen Hegde, Ashish Kumar Kakkar, Amol N Patil
Developing a latent class analysis model to identify at-risk populations among people using medicine without prescription. Expert review of clinical pharmacology 13 (12) (2020)
Rubina Mulchandani, Tanica Lyngdoh, Ashish Kumar Kakkar
Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis. European journal of clinical investigation 51 (1) (2020)
Rubina Mulchandani, Tanica Lyngdoh, Ashish Kumar Kakkar
Statins-induced hepatotoxicity: still more questions than answers. Expert opinion on drug safety 19 (12) (2020)
Prerna Chauhan, Ashish Kumar Kakkar, Harmanjit Singh, C S Gautam
Minocycline for the management of multiple sclerosis: repositioning potential, opportunities, and challenges. Expert review of neurotherapeutics 21 (1) (2020)